BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17786731)

  • 1. Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab.
    Scaramucci L; Perrotti A; Niscola P; Fratoni S; Palombi M; Piccioni D; Cupelli L; Tendas A; Dentamaro T; Del Poeta G; De Fabritiis P
    Leuk Lymphoma; 2007 Sep; 48(9):1878-80. PubMed ID: 17786731
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab maintenance for follicular lymphoma.
    Vidal L; Gafter-Gvili A; Shpilberg O
    Nat Rev Clin Oncol; 2010 Mar; 7(3):1; author reply 1. PubMed ID: 20222179
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab maintenance therapy in follicular lymphoma comes of age.
    Hiddemann W
    Leuk Res; 2006 Mar; 30 Suppl 1():S1-2. PubMed ID: 16750672
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab chemotherapy regimens for treating advanced follicular lymphoma evaluated in new study.
    Askeland G
    Expert Rev Clin Immunol; 2013 May; 9(5):402. PubMed ID: 23772446
    [No Abstract]   [Full Text] [Related]  

  • 5. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
    Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
    Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab.
    Ferrer A; López-Guillermo A; Montoto S; Estrach T; Colomo L; Montserrat E
    Ann Hematol; 2001 Aug; 80(8):479-81. PubMed ID: 11563595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary duodenal follicular lymphoma successfully treated with rituximab.
    Aguiar-Bujanda D; Quiñones-Morales I; Camacho-Galán R; Llorca-Martínez I; Rivero-Vera JC; Bohn-Sarmiento U; Aguiar-Morales J
    Clin Transl Oncol; 2007 Jul; 9(7):471-2. PubMed ID: 17652063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies.
    Nabhan C; Smith SM; Kahl BS
    Leuk Lymphoma; 2012 May; 53(5):770-8. PubMed ID: 21958083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab maintenance therapy in indolent NHL: a clinical review.
    Buske C; Hiddemann W
    Leuk Res; 2006 Mar; 30 Suppl 1():S11-5. PubMed ID: 16750673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma.
    Hagenbeek A
    Transfus Apher Sci; 2013 Aug; 49(1):43. PubMed ID: 23932512
    [No Abstract]   [Full Text] [Related]  

  • 11. Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab.
    Hirt C; Schüler F; Dölken G
    Semin Cancer Biol; 2003 Jun; 13(3):223-31. PubMed ID: 12959353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance rituximab should be considered for patients with follicular lymphoma.
    Barr PM
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
    Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
    J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
    Racila E; Link BK; Weng WK; Witzig TE; Ansell S; Maurer MJ; Huang J; Dahle C; Halwani A; Levy R; Weiner GJ
    Clin Cancer Res; 2008 Oct; 14(20):6697-703. PubMed ID: 18927313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation.
    Wake B; Hyde C; Bryan S; Barton P; Song F; Fry-Smith A; Davenport C
    Health Technol Assess; 2002; 6(3):1-85. PubMed ID: 12022936
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report.
    Croxtall JD
    BioDrugs; 2011 Oct; 25(5):329-31. PubMed ID: 21942917
    [No Abstract]   [Full Text] [Related]  

  • 17. What is the role of maintenance rituximab in follicular NHL?
    Maloney DG
    Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in gene expression patterns in follicular lymphoma and the response to rituximab.
    Bohen SP; Troyanskaya OG; Alter O; Warnke R; Botstein D; Brown PO; Levy R
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1926-30. PubMed ID: 12571354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations with newer regimens for indolent non-Hodgkin lymphoma.
    Rummel M
    Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S128-36. PubMed ID: 18952543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.
    Barker CA; Yahalom J
    J Clin Oncol; 2010 Aug; 28(24):e426; author reply e427-8. PubMed ID: 20566995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.